CD38+HLA-DR+CD8+ T cells are identified as a potential mechanistic link between Still's disease and MAS and highlight this subset as a candidate therapeutic target.
Abstract
Objective
Still's disease (SD) is an autoinflammatory disorder characterized by remarkably high IL-18 levels. Increasing evidence suggests that adaptive immunity also contributes to its pathogenesis, particularly in refractory courses. Macrophage activation syndrome (MAS), one of SD's most severe complications, is associated with further IL-18 elevation and expansion of CD38+HLA-DR+CD8+ T cells. However, whether and when this population emerges during SD remains unknown. We therefore examined CD38+HLA-DR+CD8+ T cells across disease stages.
Methods
CD38+HLA-DR+CD8+ T cells were analyzed longitudinally: at SD-onset (therapy-naïve; n=19), during clinically inactive disease (n=15), and prior to or at MAS occurrence (n=12). Spectral flow cytometry and bulk RNA-sequencing were performed. Correlations with clinical and laboratory parameters were assessed. In vitro cytokine stimulations of healthy donor (HD)-derived PBMCs and CD8+ lymphocytes were performed to explore mechanisms driving differentiation of these cells.
Results
CD38+HLA-DR+CD8+ T cells were expanded from SD-onset and peaked in MAS (median: 4.61% and 31.7%, respectively, versus 0.87% in HD). Transcriptomic profiling of these cells revealed enrichment of activation, cytotoxicity, and proliferation programs, which were confirmed at the protein level. Frequencies correlated with markers of systemic inflammation, T-cell activation, and serum IL-18 levels. Sustained IL-18 stimulation in vitro induced robust and persistent expansion of CD38+HLA-DR+CD8+ cells, recapitulating key ex vivo phenotypic features.
Conclusion
CD38+HLA-DR+CD8+ cells, previously primarily associated with MAS, are detectable early in SD. Persistent IL-18 exposure promotes their expansion. These findings identify CD38+HLA-DR+CD8+ T cells as a potential mechanistic link between SD and MAS and highlight this subset as a candidate therapeutic target.
Ex vivo data mining allowed us to integrate ex vivo clinical and immunological data, revealing a central role for CD8+CD25+ cells in ATL survival and HIT-BAY might serve as a prototype to model immune response and facilitate biomarker and therapeutic target discovery in real-world cohorts, including rare malignancies.
Ricardo Khouri, G. Silva-Santos, L. D. de Moraes et al.· Tumour Virus Research· 0 citations
Assessment of circulating Th17 and CD4+ T-cell populations and serum levels of IL-17 and IL-22 in psoriasis patients shows integration of environmental factors and microbial co-factors must be incorporated into cellular and cytokine immune response profiles in order to better understand psoriasis.
Heyam Qaid Mohammed Al-Kenani· Biobacta Journal of Biochemi...· 0 citations
Findings highlighted CD73 as a potential marker of immune dysregulation, which may be associated with the activation- and function-related cellular phenotypes, which may be associated with disease activity and clinical manifestations of SLE patients.
Rui Ma, Wen-Jie Yu, Yun-Xian Yang et al.· Immunology· 0 citations
BACKGROUND
T lymphocytes play a crucial role in the development of hypertension and associated end-organ damage. CD38 is a well-established surface marker for T-cell activation. However, clinical evidence linking CD38+ T cells, or other specific T-cell subsets, with blood pressure (BP) changes remains limited. We there...
Peripheral CHOP+ CD4+ T-cell subsets are quantitatively reduced and serologically linked to autoantibody production in pSS, highlighting CHOP expression as a potential blood biomarker and mechanistic target in pSS.
Xiao-Chen Sun, Rui-Qing Liu, Ya-Xin Li et al.· Immunology Letters· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.